Inventiva
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
50 Rue De Dijon, Daix, Bourgogne-Franche...Phone Number
+33 380447500Website
www.inventivapharma.comRevenue
<$5 MillionStock Symbol
IVAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company headquartered in France, specializing in the development of oral small molecule therapies. The company focuses on addressing significant unmet medical needs in areas such as fibrosis, lysosomal storage disorders, and oncology, aiming to advance innovative treatments that improve patient outcomes.Explore more
Inventiva Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inventiva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Inventiva launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Inventiva had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Inventiva, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Inventiva
Funding: Get notified immidiatlly once Inventiva has new funding data
Earning: See what the market has to say on Inventiva recently announced quarterly report
Check out if Inventiva is spiking on competitors!
Check if Inventiva has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Inventiva as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Inventiva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inventiva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inventiva.
Inventiva financials insights
Gather financial insights about Inventiva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$16.4M
Stock Offering
$107.7M
2023
Share Placement
$36.7M
2024
Private Equity
$99.6M
2025
Debt
$131M
2026
Debt
$151.2M
Inventiva Tech Stack
A closer look at the technologies used by Inventiva
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Inventiva News & Media
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that it has entered into agreements for a comprehensive refinancing transaction, consisting of (i) the repayment in full of the existing European Investment Bank (the "EIInventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market atInventiva Reports 2026 First Quarter Financial Information¹
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first quarter of 2026, including its cash, cash equivalents and revenues.Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain will present at at the upcoming 2026 Jefferies Global Healthcare Conference. The conference is being held June 2-4, 2026, in New York City.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inventiva
Sign Up For FreeTo access detailed company insights
Inventiva is a clinical-stage biopharmaceutical company headquartered in France, specializing in the development of oral small molecule therapies. The company focuses on addressing significant unmet medical needs in areas such as fibrosis, lysosomal storage disorders, and oncology, aiming to advance innovative treatments that improve patient outcom... Read More
